The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Compounds · Semaglutide

Comparing the STEP programme populations: who was actually enrolled

Solved
Solved by n.norgaard in post #3
Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.

Jump to the accepted answer →

LV
l.vukovicTL2 Moderator7 Mar 2026#1

Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did.

Comparing STEP 1 (N Engl J Med, 2021) with FLOW (N Engl J Med, 2024) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

9 likes 5mo
BP
baseline_peakTL2Member24 Apr 2026#2

Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.

0 likes 3mo
NN
n.norgaardTL2 Moderator Solution28 May 2026#3

Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.

27 likes 2mo

Suggested topics

TopicParticipantsRepliesViewsActivity
What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset
Asking directly, because I could not find a straight answer: What the published dose-response for semaglutide actually looks like above 2.4 mg — a second dataset Session topic: SURMOUNT-1 ( N Engl J Med ,…
VBELIGRAC+112 130 2.2k 16mo
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…
IBDNOFID+15 19 4.4k 13mo
What SELECT changed about how semaglutide is discussed, and what it did not
Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
PFTVVDEMB+120 132 2k 14mo
Molecular mass of semaglutide and why the figure differs between sources
Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…
RSRMCWACDM+101 110 12k 16h
Molecular mass of semaglutide and why the figure differs between sources — does this still hold?
Molecular mass of semaglutide and why the figure differs between sources — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 (…
ANHMLSEVT+94 102 14k 19mo

Related topics — sharing the tags SELECT trial, STEP programme, semaglutide

TopicParticipantsRepliesViewsActivity
Reverse causation in a cohort study of weight and outcome
On the subject in the title: Reverse causation in a cohort study of weight and outcome Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with FLOW ( N Engl J Med , 2024) and…
LVDRIEDDN+10 14 11k 7mo
When a dose reduction is the correct response to a side effect — a second dataset
When a dose reduction is the correct response to a side effect — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on…
HSSMMMDPT+10 14 42k 2mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on
Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med…
GOGTMMDSRM+122 136 48k 9mo
Second pass at: A pooled estimate that changed when one trial was added
On the subject in the title: Second pass at: A pooled estimate that changed when one trial was added Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
FLSTYAWNRM+26 30 22k 1mo
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version
Posting this under the heading it deserves: Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Everything below is what sits behind that. Reporting something rather than…
JSSSIBSBSO+138 148 1.8k 2y